Access to Dibotatug (DR-01) Outside Regular Clinical Trials
This program allows patients with certain conditions who cannot access Dibotatug (DR-01) through standard clinical trials to receive the investigational drug through an expanded access pathway. It's designed for eligible patients who may benefit from this treatment and have no other available options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a serious or life-threatening condition that Dibotatug may help treat
- You cannot qualify for an active Dibotatug clinical trial or it is not available to you
- Your doctor believes you may benefit from Dibotatug treatment
- You meet basic safety requirements (no severe organ damage or other serious medical conditions that would make the drug unsafe)
- You are willing to work with your healthcare team to monitor your response to treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called dibotatug (DR-01) for adults with certain types of bone marrow failure, such as severe aplastic anemia or non-severe aplastic anemia that has not responded to or has returned after prior treatment. The study aims to see if the drug is safe and effective.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This early-phase study tests DR-01 to treat large granular lymphocytic leukemia (LGLL) or certain aggressive T-cell or cytotoxic lymphomas. It aims to see whether the drug is safe and can shrink or control the cancer.
This trial tests a new drug called Dato-DXd for people with a specific type of breast cancer that is hormone receptor-positive and HER2-negative (IHC 0). It's for those whose cancer has stopped responding to hormone therapy and who haven't had chemotherapy for cancer that has spread.
This trial tests a new drug, BioTTT001, given as a shot directly into tumors. It is for people with certain advanced solid tumors that have stopped responding to standard treatments or who have no other options.